NCT03362086

Brief Summary

Osteosarcoma is very rare bone tumor. The investigator set up the biobank to ensure the patients has the chance to participate in future research

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
180

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Feb 2018

Longer than P75 for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 26, 2017

Completed
9 days until next milestone

First Posted

Study publicly available on registry

December 5, 2017

Completed
2 months until next milestone

Study Start

First participant enrolled

February 1, 2018

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2021

Completed
3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2024

Completed
Last Updated

December 5, 2017

Status Verified

December 1, 2017

Enrollment Period

3 years

First QC Date

November 26, 2017

Last Update Submit

December 2, 2017

Conditions

Osteosarcoma

Keywords

bone tumor osteosarcoma

Outcome Measures

Primary Outcomes (1)

  • Examine VEGFR-2 and PD-L1 gene expression osteosarcoma

    To examine the VEGFR2 and programmed cell death ligand 1 (PD-L1) genes expression of the patients with osteosarcoma.And Analyze their differences.

    3 years

Eligibility Criteria

Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

the patients diagnosed with osteosarcoma without pulmonary metastasis

You may not qualify if:

  • non-asian pulmonary metastasis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Biospecimen

Retention: SAMPLES WITHOUT DNA

The investigator will collect pecimen and blood

MeSH Terms

Conditions

Osteosarcoma

Condition Hierarchy (Ancestors)

Neoplasms, Bone TissueNeoplasms, Connective TissueNeoplasms, Connective and Soft TissueNeoplasms by Histologic TypeNeoplasmsSarcoma

Study Officials

  • Tingting Ren, phD

    Peking University People's Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Kuisheng Liu, phD

CONTACT

+8601088324471liukuisheng01@163.com

Study Design

Study Type
observational
Observational Model
FAMILY BASED
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Lab manager of Musculoskeletal Tumor Center

Study Record Dates

First Submitted

November 26, 2017

First Posted

December 5, 2017

Study Start

February 1, 2018

Primary Completion

February 1, 2021

Study Completion

February 1, 2024

Last Updated

December 5, 2017

Record last verified: 2017-12